Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02982915 · ClinicalTrials.gov registry record · Phase 1
Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty
A Phase 1 study, sponsored by Longeveron.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02982915: Completed Phase 1 study, sponsored by Longeveron.
NCT02982915 is a Phase 1 study that has completed, run by Longeveron. The registered enrollment target is 62 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02982915, a Phase 1 study, has completed, sponsored by Longeveron.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.
Primary Outcome
* Is life-threatening (e.g., stroke or non-fatal pulmonary embolism). * Requires inpatient hospitalization or prolongation of existing hospitalization. * Results in persistent or significant disability/incapacity. * Results in death * Results in other clinically significant untoward laboratory test result(s) or medical condition(s), determined per Investigator's judgment.
Interventions
- BIOLOGICAL Fluzone High Dose Vaccine
- BIOLOGICAL Longeveron Mesenchymal Stem Cells (LMSCs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-11 |
| Est. Completion | 2022-09 |
| Phase | Phase 1 |
What the finished NCT02982915 record still lists
NCT02982915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Fluzone High Dose Vaccine is the first listed.
NCT02982915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02982915 about?
NCT02982915 is a clinical study titled "Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty". This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.
What is the current status of trial NCT02982915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2016-11. Estimated completion is 2022-09.
What interventions are being tested in trial NCT02982915?
The interventions under investigation include: Fluzone High Dose Vaccine (BIOLOGICAL), Longeveron Mesenchymal Stem Cells (LMSCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02982915?
This trial is sponsored by Longeveron, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02982915's enrollment target sits among peer trials
62 824th of 2000 higher than 1,173 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia